Antihypertensive Drug Guanabenz Is Active In Vivo against both Yeast and Mammalian Prions

Abstract

GA thus adds to the short list of compounds active in vivo in animal models for the treatment of prion-based diseases. Because it has been administrated for many years to treat hypertension on a daily basis, without major side-effects, our results suggest that it could be evaluated in human as a potential treatment for prion-based diseases.